Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs-Reference-Cited by-同舟云学术

Sputum cell‐free DNA: Valued surrogate sample for the detection of EGFR exon 20 p.T790M mutation in patients with advanced lung adenocarcinoma and acquired resistance to EGFR‐TKIs

Published:2021-05 Issue:10 Volume:10 Page:3323-3331
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Wang Zheng¹,Li Xiaoguang²,Zhang Lin¹,Xu Yan³,Wang Mengzhao³^ORCID,Liang Li⁴,Jiao Peng⁵,Li Yuanming²,He Shurong¹,Du Jun¹,He Lei¹,Tang Min⁶,Sun Mingjun¹,Yang Li¹,Di Jing¹,Zhu Guanshan⁷,Li Lin⁶,Liu Dongge¹^ORCID

Affiliation:

1. Department of Pathology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical Sciences Beijing P.R. China

2. Department of Minimally Invasive Tumor Therapies Center Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical Sciences Beijing P.R. China

3. Department of Respiratory and Critical Care Medicine Peking Union Medical College HospitalChinese Academy of Medical SciencesPeking Union Medical College Beijing P.R. China

4. Department of Cancer chemotherapy and Radiation sickness Peking University Third Hospital Beijing P.R. China

5. Department of Thoracic Surgery Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical Sciences Beijing P.R. China

6. Department of Medical Oncology Beijing HospitalNational Center of GerontologyInstitute of Geriatric MedicineChinese Academy of Medical Sciences P.R. China

7. Amoy Diagnostics Co., Ltd Xiamen P.R. China

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Cancer Research,Radiology, Nuclear Medicine and imaging,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cam4.3817

Reference30 articles.

1. EGFR T790M and C797S Mutations as Mechanisms of Acquired Resistance to Dacomitinib

2. Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer